Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

(2014) Neil Desai et al.   Translational Oncology

Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer

(2013) Matthias Maak et al.   ANNALS OF SURGERY

EMT is the dominant program in human colon cancer

(2013) Andre Loboda et al.   BMC Medical Genomics

Colon cancer molecular subtypes identified by expression profiling and associatedto stroma, mucinous type and different clinical behavior

(2012) Beatriz Perez Villamil et al.   BMC CANCER

Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications

(2012) F. A. Sinicrope et al.   CLINICAL CANCER RESEARCH

A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency

(2012) Sun Tian et al.   JOURNAL OF PATHOLOGY

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer

(2011) Sang Cheul Oh et al.   GUT

Targeted therapies for breast cancer

(2011) Michaela J. Higgins et al.   JOURNAL OF CLINICAL INVESTIGATION

Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer

(2011) Gordon Hutchins et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

(2010) Ramon Salazar et al.   JOURNAL OF CLINICAL ONCOLOGY

Microsatellite instability in colorectal cancer—the stable evidence

(2010) Eduardo Vilar et al.   Nature Reviews Clinical Oncology

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

(2010) A Singh et al.   ONCOGENE

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

(2009) Kristy J. Gotink et al.   ANGIOGENESIS

Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

(2009) Daniel Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

(2009) Arnaud D. Roth et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

(2008) Neil P. Desai et al.   ANTI-CANCER DRUGS

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

(2008) S. Ogino et al.   GUT